Southeast Asia’s first GMP-compliant CDMO for viral vector manufacturing CellVec Pte Ltd announced a strategic partnership with Australia’s Peter MacCallum Cancer Centre (Peter Mac) to manufacture and supply lentiviral vectors for their in-house pipeline of cell-based immunotherapies for the treatment of cancer. In CellVec’s first strategic relationship with a leading Australian cancer research centre, the partnership connects the regional specialist in viral vector manufacturing and the leading integrated cancer institution, marking a significant milestone for the 4-year-old company in its mission of innovating for patient benefit by facilitating the development of cancer therapies amidst a long-standing global shortage of lentiviral vectors.
For Peter Mac, CellVec stood out as a partner for lentiviral vector supply based on the strong credentials and extensive prior experience of CellVec’s scientific team, led by Dr. Lucas Chan, in GMP-compliant lentiviral vector technologies and manufacturing. This, combined with the fact that they are co-located in the Asia Pacific region, presented an opportunity to partner locally to overcome bottlenecks in supply of this crucial component of cell-based immunotherapy manufacturing.
Professor Simon Harrison, Director of the Centre of Excellence in Cellular Immunotherapy and a leading haematologist in the myeloma team at Peter Mac said, “this partnership with CellVec will underpin and enable a pipeline of high-potential research focused on developing the next generation of immunotherapies.”
Associate Professor Jane Oliaro, Chief Scientist for the Centre of Excellence in Cellular Immunotherapy Translation Laboratory at the Peter Mac, said “the enormous potential for cell-based immunotherapies to treat cancer simply cannot be realised without an assured supply of these vectors for our preclinical development program, and ultimately clinical application.”
“CellVec’s mission has always been to innovate for patient benefit, which means lowering the cost of treatments while pushing the boundaries of innovation so more people can access the treatment they need,” said Dr. Gayatri Sharma, Chief Commercial Officer of CellVec. “This marks a new chapter for us in the cancer space where our scientific and research capabilities can leave great impact—we are honoured and excited to embark on this meaningful partnership with a world-class institution like Peter Mac to reach more cancer patients within Australia.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!